-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, the official website of NMPA showed that Shanxi Pude Pharmaceutical Co.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
Flurbiprofen axetil injection is a non-steroidal anti-inflammatory analgesic, which can effectively control pain while no longer addictive, and has no central inhibitory effect, which is conducive to the recovery of patients after surgery
.
.
Sales of terminal flurbiprofen in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2020, the sales of terminal flurbiprofen in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan
.
.
Among them, flurbiprofen gel plaster accounted for 67.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
Currently, there are only three flurbiprofen products on the market in China, including flurbiprofen axetil injection, flurbiprofen gel plaster and flurbiprofen sustained-release tablets
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
Data source: Mi Neiwang database, NMPA
On December 22, the official website of NMPA showed that Shanxi Pude Pharmaceutical Co.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
Flurbiprofen axetil injection is a non-steroidal anti-inflammatory analgesic, which can effectively control pain while no longer addictive, and has no central inhibitory effect, which is conducive to the recovery of patients after surgery
.
.
Sales of terminal flurbiprofen in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2020, the sales of terminal flurbiprofen in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan
.
.
Among them, flurbiprofen gel plaster accounted for 67.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
Currently, there are only three flurbiprofen products on the market in China, including flurbiprofen axetil injection, flurbiprofen gel plaster and flurbiprofen sustained-release tablets
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
Data source: Mi Neiwang database, NMPA
On December 22, the official website of NMPA showed that Shanxi Pude Pharmaceutical Co.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
, Ltd.
was approved to market the flurbiprofen axetil injection with imitation of three types of applications, making it the third domestic company
.
Flurbiprofen is an analgesic drug with terminal sales of more than 2 billion yuan in public medical institutions in China in 2020
.
Flurbiprofen axetil injection is a non-steroidal anti-inflammatory analgesic, which can effectively control pain while no longer addictive, and has no central inhibitory effect, which is conducive to the recovery of patients after surgery
.
.
Sales of terminal flurbiprofen in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2020, the sales of terminal flurbiprofen in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan
.
Hospital hospital hospital.
Among them, flurbiprofen gel plaster accounted for 67.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
58%, a year-on-year increase of 27.
98%; flurbiprofen injection accounted for 32.
42%, a year-on-year decline of 60.
70%
.
As the first batch of collectively collected varieties, flurbiprofen axetil injection "traded price for quantity", and the market scale was "halved"
.
Currently, there are only three flurbiprofen products on the market in China, including flurbiprofen axetil injection, flurbiprofen gel plaster and flurbiprofen sustained-release tablets
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
.
Prior to this, the only manufacturers of flurbiprofen axetil injection were Beijing Tide (originally researched for localization) and Wuhan Daan, and Shanxi Pude Pharmaceutical Co.
, Ltd.
was the third domestic manufacturer of this product
.
Data source: Mi Neiwang database, NMPA
